Sanford-Burnham presents at AACR April 19-22
The American Association of Cancer Research (AACR) Annual Meeting, held April 18-22 in Philadelphia, will attract approximately 18,000 attendees from around the world. They are coming to hear from an outstanding roster of speakers, hundreds of live talks, and more than 6,000 proffered papers from scientists and clinicians around the world. This year’s theme, “Brining Cancer Discoveries to patients,” highlights the need to link laboratory discoveries to treatments for the purpose of finding cancer cures.
Sanford-Burnham’s Cancer Center, one of seven NCI-designated basic research centers in the nation, will have a strong presence at the event. Our Institute aligns basic cancer research with translational research and drug discovery and development to achieve our mission to overcome cancer as a cause of human suffering and death.
To learn more about our accomplishments and contributions to cancer research, visit us at the following venues at AACR:
April 19 PRESENTATIONS Sunday, 1:00 p.m. - 3:00 p.m. Major Symposium Autophagy and Cancer 1:35 p.m. – 1:55 p.m. Autophagy and metabolic reprogramming in the tumor stroma Jorge Moscat, Ph.D., associate director for Basic Research, NCI-Designated Cancer Center
POSTERS Sunday, 1:00 p.m. -5:00 p.m. Modeling Cancer Prevention Influence of high-fat diet and APC status on epigenetic regulation of FXR in colon cells Jeffrey Smith, Ph.D., professor in the NCI-Designated Cancer Center
Long Non-Coding RNAs Identification of a novel long noncoding RNA as a mediator for CRTC1-MAML2 fusion oncogenic function and a biomarker for CRTC1-MAML2 fusion-positive tumors Jian-Liang Li, associate director, Bioinformatics
April 20 PRESENTATIONS Monday, 1:00 p.m. – 3:00 p.m. Recent Advances in Diagnostics and Therapeutics Research Novel Delivery Systems and/or Formulations in Cancer Treatment 2:00 p.m. – 2:15 p.m. A novel endocytic and intracellular transport pathway for drug delivery across blood vessels and into nutrient-deprived tumor cells Hongo Pang, Ph.D., postdoctoral researcher (laboratory of Erkki Ruoslahti, M.D., Ph.D.)
POSTERS Monday, 1 p.m. – 5:00 p.m. MAPK, EGFR, and BTK Inhibitors Refinement of inhibitors of the KRAS-signaling naocluster protein, CNKSR1, that block oncogenic KRAS signaling and growth Garth Powis, D.Phil., Jeanne and Gary Herberger Leadership Chair in Cancer Research, and director of the NCI-Designated Cancer Center
Mouse Models of Human Cancer 1 Generation and characterization of a mouse model of CRTC1-MAML2-induced mucoepidermoid carcinoma (MEC) Jian-Liang Li, associate director, Bioinformatics
Preclinical Targeted Therapy Co-targeting ROS and CLU-mediated stress response using SMIP004 (a novel inducer of ROS and cancer cell selective apoptosis) and OGX—011 in MDV3100-resistant castrate-resistant prostate cancer Dieter Wolf, Ph.D., professor in the NCI-Designated Cancer Center
April 21 PRESENTATIONS Tuesday, 10:30 a.m. – 12:30 p.m. Recent Advances in Organ Site Research Elucidating Mechanisms that Underlie the Development of Pediatric Brain Cancer 11:45 a.m. – 12:05 p.m. Drivers and Drugs for Medulloblastoma Robert Wechsler-Reya, Ph.D., professor in NCI-Designated Cancer Center
POSTERS Tuesday, 1:00 p.m. – 5:00 p.m. Novel Targets 1 Identification of a small-molecule inhibitor of aldolase A for the targeting of hypoxic cancer cells Garth Powis, D.Phil., Jeanne and Gary Herberger Leadership Chair in Cancer Research, and director of the NCI-Designated Cancer Center Accelerated drug discovery platform yields synthesis of novel stearoyl-CoA desaturase 1 inhibitors that demonstrate anti-tumor efficacy in several models of aggressive cancer Anthony Pinkerton, Ph.D., director of Chemistry
MINISYMPOSIUM Tuesday, 3:00 p.m.-5:00 p.m. Precision Medicine in the Clinic Identification of novel drugs for glioblastoma using chemical biology fingerprinting Kristiina Vuori, M.D., Ph.D., president, Pauline and Stanley Foster Presidential Chair, and professor in the NCI-Designated Cancer Center
April 22 POSTERS Wednesday, 8:00 a.m. – 12:00 p.m. Drug Delivery Deciphering the basis of CendR-mediated penetration into tumors Erkki Ruoslahti, M.D., Ph.D., distinguished professor in the NCI-Designated Cancer Center